The US Federal Trade Commission (FTC) has requested additional information from Roche and Spark Therapeutics regarding Roche’s pending $4.3-billion acquisition of Spark.
On June 10, 2019, Roche and Spark Therapeutics, a Philadelphia, PA-based company focused on gene therapies, announced that they received a request for additional information and a request for documentary material (second request) from the US Federal Trade Commission (FTC) regarding FTC’s review of Roche’s pending $4.3-billion acquisition of Spark. Also, the UK Competition and Markets Authority (CMA) opened an investigation to obtain further information in relation to the proposed acquisition.
As a result of the second request, Roche has extended the offering period of its previously announced tender offer to purchase all shares of Spark for $114.50 per share in cash. The offer, which was previously scheduled to expire on Friday, June 14, 2019, has been extended until July 31, 2019. All terms and conditions of the offer shall remain unchanged during the extended period.
CMA’s separate investigation will determine whether the department considers that it has jurisdiction over the acquisition and if so, whether CMA considers that the acquisition may be expected to result in a substantial lessening of competition in the UK such as to warrant a more detailed, Phase II review. Pending the outcome of its investigation, the CMA has issued an interim enforcement order that would become effective upon closing of the transaction and would require Roche to hold separate the Spark business. The companies are working cooperatively with the CMA and will continue to do so, according to Roche.
Closing of the tender offer is dependent on customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and tendering and receiving a majority of the outstanding Spark shares.
Source: Roche
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.